Architect Therapeutics Inc. has identified new spiro heterocyclic cyclin-dependent kinase 2 (CDK2) inhibitors potentially useful for the treatment of cancer, myeloproliferative, autoimmune disease, inflammatory disorder, viral infections and fibrosis.